{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:59:34Z","timestamp":1787961574697,"version":"build-2784847793"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T00:00:00Z","timestamp":1713139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hormones"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s42000-024-00549-8","type":"journal-article","created":{"date-parts":[[2024,4,15]],"date-time":"2024-04-15T08:01:56Z","timestamp":1713168116000},"page":"183-204","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["EndoBridge 2023: highlights and pearls"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1797-7662","authenticated-orcid":false,"given":"Bulent Okan","family":"Yildiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar Luiz","family":"Boguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret Cristina","family":"da Silva Boguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozlem","family":"Celik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada El-Hajj","family":"Fuleihan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios G.","family":"Goulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Hammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan R.","family":"Haymart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Kaltsas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Law","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda Yuan Ling","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Luger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djuro","family":"Macut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"McClung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander Dimitri","family":"Miras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Elizabeth","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin P.","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duarte","family":"Pignatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamayle","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sipos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine A.","family":"Stratakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Tsoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. J.","family":"van der Lely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma F.","family":"Witchel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dilek","family":"Yazici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,15]]},"reference":[{"key":"549_CR1","doi-asserted-by":"publisher","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","volume":"105","author":"SL Samson","year":"2020","unstructured":"Samson SL, Nachtigall LB, Fleseriu M et al (2020) Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide. J Clin Endocrinol Metab 105:e3785\u2013e3797. https:\/\/doi.org\/10.1210\/clinem\/dgaa526","journal-title":"J Clin Endocrinol Metab"},{"key":"549_CR2","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1210\/jc.2014-4113","volume":"100","author":"S Melmed","year":"2015","unstructured":"Melmed S, Popovic V, Bidlingmaier M et al (2015) Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial. J Clin Endocrinol Metab 100:1699\u20131708. https:\/\/doi.org\/10.1210\/jc.2014-4113","journal-title":"J Clin Endocrinol Metab"},{"key":"549_CR3","doi-asserted-by":"crossref","unstructured":"Madan\u00a0A,\u00a0Zhu\u00a0YF,\u00a0Markison\u00a0S et al\u00a0(2019) Final results from the first in man phase 1 clinical trial of CRN00808, an orally bioavailable sst2-selective, nonpeptide somatostatin biased agonist, for the treatment of acromegaly: safety, pharmacokinetics, pharmacodynamics, and midazolam drug interaction in healthy volunteers. J Endocr Soc 3(Suppl-1):SAT\u2013249","DOI":"10.1210\/js.2019-SAT-429"},{"key":"549_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100588","volume":"296","author":"R Basu","year":"2021","unstructured":"Basu R, Nahar K, Kulkarni P et al (2021) A novel peptide antagonist of the human growth hormone receptor. J Biol Chem 296:100588. https:\/\/doi.org\/10.1016\/j.jbc.2021.100588","journal-title":"J Biol Chem"},{"key":"549_CR5","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1001\/jamainternmed.2021.2686","volume":"181","author":"JP Brito","year":"2021","unstructured":"Brito JP, Ross JS, El Kawkgi OM, Maraka S, Deng Y, Shah ND, Lipska KJ (2021) Levothyroxine use in the United States, 2008\u20132018. JAMA Intern Med 181:1402\u20131405. https:\/\/doi.org\/10.1001\/jamainternmed.2021.2686","journal-title":"JAMA Intern Med"},{"key":"549_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1530\/EJE-21-0485","volume":"185","author":"JL la Cour","year":"2021","unstructured":"la Cour JL, Medici BR, Grand MK, Nicolaisdottir DR, Lind B, Faber J, Andersen CL, Nygaard B (2021) Risk of over- and under- treatment with levothyroxine in primary care in Copenhagen, Denmark. Eur J Endocrinol 185:673\u2013679. https:\/\/doi.org\/10.1530\/EJE-21-0485","journal-title":"Eur J Endocrinol"},{"key":"549_CR7","doi-asserted-by":"publisher","unstructured":"Stott DJ, Rodondi N, Kearney PM et al; TRUST Study Group (2017) Thyroid hormone therapy for older adults with subclinical hypothyroidism. N Engl J Med 376:2534\u20132544. https:\/\/doi.org\/10.1056\/NEJMoa1603825","DOI":"10.1056\/NEJMoa1603825"},{"key":"549_CR8","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1056\/NEJMcp1611144","volume":"376","author":"RP Peeters","year":"2017","unstructured":"Peeters RP (2017) Subclinical hypothyroidism. N Engl J Med 376:2556\u20132565. https:\/\/doi.org\/10.1056\/NEJMcp1611144","journal-title":"N Engl J Med"},{"key":"549_CR9","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrendo.2017.93","volume":"13","author":"TIM Korevaar","year":"2017","unstructured":"Korevaar TIM, Medici M, Visser TJ, Peeters RP (2017) Thyroid disease in pregnancy: new insights in diagnosis and clinical management. Nat Rev Endocrinol 13:610\u2013622. https:\/\/doi.org\/10.1038\/nrendo.2017.93","journal-title":"Nat Rev Endocrinol"},{"key":"549_CR10","doi-asserted-by":"publisher","first-page":"108","DOI":"10.3348\/kjr.2019.0215","volume":"21","author":"Y Yim","year":"2020","unstructured":"Yim Y, Na DG, Ha EJ et al (2020) Concordance of three international guidelines for thyroid nodules classified by ultrasonography and diagnostic performance of biopsy criteria. Korean J Radiol 21:108\u2013116. https:\/\/doi.org\/10.3348\/kjr.2019.0215","journal-title":"Korean J Radiol"},{"key":"549_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.surg.2022.06.061","volume":"173","author":"KM Ramonell","year":"2023","unstructured":"Ramonell KM, Ohori NP, Liu JB et al (2023) Changes in thyroid nodule cytology rates after institutional implementation of the thyroid imaging reporting and data system. Surgery 173:232\u2013238. https:\/\/doi.org\/10.1016\/j.surg.2022.06.061","journal-title":"Surgery"},{"key":"549_CR12","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research N","year":"2014","unstructured":"Cancer Genome Atlas Research N (2014) Integrated genomic characterization of papillary thyroid carcinoma. Cell 159:676\u201390. https:\/\/doi.org\/10.1016\/j.cell.2014.09.050","journal-title":"Cell"},{"key":"549_CR13","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1089\/thy.2023.0141","volume":"33","author":"SZ Ali","year":"2023","unstructured":"Ali SZ, Baloch ZW, Cochand-Priollet B, Schmitt FC, Vielh P, VanderLaan PA (2023) The 2023 Bethesda system for reporting thyroid cytopathology. Thyroid 33:1039\u20131044. https:\/\/doi.org\/10.1089\/thy.2023.0141","journal-title":"Thyroid"},{"key":"549_CR14","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1089\/thy.2021.0659","volume":"32","author":"TX Hu","year":"2022","unstructured":"Hu TX, Nguyen DT, Patel M et al (2022) The effect modification of ultrasound risk classification on molecular testing in predicting the risk of malignancy in cytologically indeterminate thyroid nodules. Thyroid 32:905\u2013916. https:\/\/doi.org\/10.1089\/thy.2021.0659","journal-title":"Thyroid"},{"key":"549_CR15","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1097\/SLA.0b013e31824deae6","volume":"255","author":"H In","year":"2012","unstructured":"In H, Neville BA, Lipsitz SR et al (2012) The role of National Cancer Institute-designated cancer center status: observed variation in surgical care depends on the level of evidence. Ann Surg 255:890\u20135. https:\/\/doi.org\/10.1097\/SLA.0b013e31824deae6","journal-title":"Ann Surg"},{"key":"549_CR16","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1136\/bmj.327.7419.864","volume":"327","author":"G Elwyn","year":"2003","unstructured":"Elwyn G, Edwards A, Britten N (2003) What information do patients need about medicines? \u201cDoing prescribing\u201d: how doctors can be more effective. BMJ. 327:864\u20137. https:\/\/doi.org\/10.1136\/bmj.327.7419.864","journal-title":"BMJ."},{"key":"549_CR17","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1200\/JCO.18.02228","volume":"37","author":"L Wallner","year":"2019","unstructured":"Wallner L, Reyes-Gastelum D, Hamilton AS, Ward KC, Wawley ST, Haymart MR (2019) JCO 37:2152\u20132161. https:\/\/doi.org\/10.1200\/JCO.18.02228","journal-title":"JCO"},{"key":"549_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1089\/thy.2021.0666","volume":"32","author":"R Chou","year":"2022","unstructured":"Chou R, Dana T, Brent GA et al (2022) Serum thyroglobulin measurement following surgery without radioactive iodine for differentiated thyroid cancer: a systematic review. Thyroid 32:613\u201339. https:\/\/doi.org\/10.1089\/thy.2021.0666","journal-title":"Thyroid"},{"key":"549_CR19","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s11764-020-00937-0","volume":"15","author":"M Papaleontiou","year":"2021","unstructured":"Papaleontiou M, Zebrack B, Reyes-Gastelum D et al (2021) Physician management of thyroid cancer patients\u2019 worry. J Cancer Surviv 15:418\u2013426. https:\/\/doi.org\/10.1007\/s11764-020-00937-0","journal-title":"J Cancer Surviv"},{"key":"549_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/MED.0000000000000815","volume":"30","author":"P Haymart","year":"2023","unstructured":"Haymart P, Levin NJ, Haymart MY (2023) The psychosocial impact of thyroid cancer. Curr Opin Endocrinol Diabetes Obes 30:252\u2013258. https:\/\/doi.org\/10.1097\/MED.0000000000000815","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"549_CR21","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/jbmr.3884","volume":"34","author":"R Bouillon","year":"2019","unstructured":"Bouillon R, Bikle D (2019) Vitamin D metabolism revised: fall of dogmas. J Bone Miner Res. 34:1985\u20131992. https:\/\/doi.org\/10.1002\/jbmr.3884","journal-title":"J Bone Miner Res."},{"key":"549_CR22","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1210\/clinem\/dgab742","volume":"107","author":"M Chakhtoura","year":"2022","unstructured":"Chakhtoura M, Bacha D, Gharios C et al (2022) Vitamin D supplementation and fractures in adults: a systematic umbrella review of meta-analyses of controlled trials. J Clin Endocrinol Metab 107:882\u2013898. https:\/\/doi.org\/10.1210\/clinem\/dgab742","journal-title":"J Clin Endocrinol Metab"},{"key":"549_CR23","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1210\/clinem\/dgad225","volume":"108","author":"AR Cappola","year":"2023","unstructured":"Cappola AR, Auchus RJ, El-Hajj Fuleihan G et al (2023) Hormones and ageing: an endocrine society scientific position statement. J Clin Endocrinol Metabol 108:1835\u20131874. https:\/\/doi.org\/10.1210\/clinem\/dgad225","journal-title":"J Clin Endocrinol Metabol"},{"key":"549_CR24","unstructured":"Vitamin D for the prevention of disease: an endocrine society clinical practice guideline survey (http:\/\/surveymonkey.com)"},{"key":"549_CR25","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/jbmr.4888","volume":"38","author":"R Bouillon","year":"2023","unstructured":"Bouillon R, LeBoff M, Neale RE (2023) Health effects of vitamin D supplementation: lessons learned from randomized controlled trials and mendelian randomization studies. J Bone Miner Res 38:1391\u20131403. https:\/\/doi.org\/10.1002\/jbmr.4888","journal-title":"J Bone Miner Res"},{"key":"549_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/gme.0b013e3181ade8e5","volume":"17","author":"D Cerd\u00e1 Gabaroi","year":"2010","unstructured":"Cerd\u00e1 Gabaroi D, Peris P, Monegal A et al (2010) Search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause 17:135\u20139. https:\/\/doi.org\/10.1097\/gme.0b013e3181ade8e5","journal-title":"Menopause"},{"key":"549_CR27","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/BOR.0000000000000074","volume":"26","author":"SP Bours","year":"2014","unstructured":"Bours SP, van den Bergh JP, van Geel TA, Geusens PP (2014) Secondary osteoporosis and metabolic bone disease in patients 50 years and older with osteoporosis or with a recent clinical fracture: a clinical perspective. Curr Opin Rheumatol 26:430\u20139. https:\/\/doi.org\/10.1097\/BOR.0000000000000074","journal-title":"Curr Opin Rheumatol"},{"issue":"Suppl 1","key":"549_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American Association of Clinical Endocrinologists\/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26(Suppl 1):1\u201346. https:\/\/doi.org\/10.4158\/GL-2020-0524SUPPL","journal-title":"Endocr Pract"},{"issue":"Suppl B","key":"549_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1302\/0301-620X.99B4.BJJ-2016-1212.R1","volume":"99","author":"J Parvizi","year":"2017","unstructured":"Parvizi J, Shohat N, Gehrke T (2017) Prevention of periprosthetic joint infection. Bone Joint J 99(Suppl B):3\u201310. https:\/\/doi.org\/10.1302\/0301-620X.99B4.BJJ-2016-1212.R1","journal-title":"Bone Joint J"},{"key":"549_CR30","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1210\/clinem\/dgac278","volume":"107","author":"MT Korytkowski","year":"2022","unstructured":"Korytkowski MT, Muniyappa R, Antinori-Lent et al (2022) Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 107:2101\u20132128. https:\/\/doi.org\/10.1210\/clinem\/dgac278","journal-title":"J Clin Endocrinol Metab"},{"key":"549_CR31","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.bja.2023.02.039","volume":"131","author":"K Crowley","year":"2023","unstructured":"Crowley K, O Scanaill P, Hermanides J, Buggy DJ (2023) Current practice in the perioperative management of patients with diabetes mellitus: a narrative review. Brit J Anaesthesia 131:242\u2013252. https:\/\/doi.org\/10.1016\/j.bja.2023.02.039","journal-title":"Brit J Anaesthesia"},{"key":"549_CR32","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.2337\/dc21-2441","volume":"45","author":"JP Kirwan","year":"2022","unstructured":"Kirwan JP, Courcoulas AP, Cummings DE et al (2022) Diabetes remission in the alliance of randomized trials of medicine versus metabolic surgery in type 2 diabetes (ARMMS-T2D). Diabetes Care 45:1574\u20131583. https:\/\/doi.org\/10.2337\/dc21-2441","journal-title":"Diabetes Care"},{"key":"549_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(20)32649-0","volume":"397","author":"G Mingrone","year":"2021","unstructured":"Mingrone G, Panunzi S, De Gaetano A et al (2021) Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 397:293\u2013304. https:\/\/doi.org\/10.1016\/S0140-6736(20)32649-0","journal-title":"Lancet"},{"key":"549_CR34","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41574-022-00757-5","volume":"19","author":"DA Sandoval","year":"2023","unstructured":"Sandoval DA, Patti ME (2023) Glucose metabolism after bariatric surgery: implications for T2DM remission and hypoglycaemia. Nat Rev Endocrinol 19:164\u2013176. https:\/\/doi.org\/10.1038\/s41574-022-00757-5","journal-title":"Nat Rev Endocrinol"},{"key":"549_CR35","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.soard.2017.01.025","volume":"13","author":"E Suhl","year":"2017","unstructured":"Suhl E, Anderson-Haynes SE, Mulla C, Patti ME (2017) Medical nutrition therapy for post bariatric hypoglycemia: practical insights. Surg Obes Relat Dis 13:888\u2013896. https:\/\/doi.org\/10.1016\/j.soard.2017.01.025","journal-title":"Surg Obes Relat Dis"},{"key":"549_CR36","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1111\/dom.13796","volume":"21","author":"CC Ohrstrom","year":"2019","unstructured":"Ohrstrom CC, Worm D, Hojager A et al (2019) Postprandial hypoglycaemia after Roux-en-Y\u00a0gastric bypass and the effects of acarbose, sitagliptin, verapamil, liraglutide and pasireotide. Diabetes Obes Metab 21:2142\u20132151. https:\/\/doi.org\/10.1111\/dom.13796","journal-title":"Diabetes Obes Metab"},{"key":"549_CR37","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000521241","volume":"15","author":"LM Donini","year":"2022","unstructured":"Donini LM, Busetto L, Bischoff SC et al (2022) Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO Consensus Statement. Obes Facts 15:321\u201335. https:\/\/doi.org\/10.1159\/000521241","journal-title":"Obes Facts"},{"key":"549_CR38","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1017\/S0007114520002172","volume":"124","author":"JL Atkins","year":"2020","unstructured":"Atkins JL, Wannamathee SG (2020) Sarcopenic obesity in ageing: cardiovascular outcomes and mortality. Br J Nutr 124:1102\u201313. https:\/\/doi.org\/10.1017\/S0007114520002172","journal-title":"Br J Nutr"},{"key":"549_CR39","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.3945\/ajcn.2008.26950","volume":"89","author":"Y Rolland","year":"2009","unstructured":"Rolland Y, Lauwers-Cances V, Cristini C et al (2009) Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie del l\u2019OSteoporose) study. Am J Clin Nutr 89:1895\u2013900. https:\/\/doi.org\/10.3945\/ajcn.2008.26950","journal-title":"Am J Clin Nutr"},{"key":"549_CR40","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1016\/j.clnu.2019.11.024","volume":"39","author":"LM Donini","year":"2020","unstructured":"Donini LM, Busetto L, Bauer JM et al (2020) Critical appraisal of definitions and diagnostic criteria for sarcopenic obesity based on a systematic review. Clin Nutr 39:2368\u201388. https:\/\/doi.org\/10.1016\/j.clnu.2019.11.024","journal-title":"Clin Nutr"},{"key":"549_CR41","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1056\/NEJMoa1616338","volume":"376","author":"DT Villareal","year":"2017","unstructured":"Villareal DT, Aguirre L, Gurney AB et al (2017) Aerobic or resistance exercise, or both, in dieting obese older adults. N Engl J Med. 376:1943\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1616338","journal-title":"N Engl J Med."},{"key":"549_CR42","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S et al (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"549_CR43","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","volume":"389","author":"M Lincoff","year":"2023","unstructured":"Lincoff M, Brown-Frandsen K, Colhoun HM et al (2023) Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 389:2221\u20132232. https:\/\/doi.org\/10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"549_CR44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"A Jastreboff","year":"2022","unstructured":"Jastreboff A, Aronne LJ, Ahmad NN et al (2022) Tirzepatide once weekly for the treatment of obesity. N Engl J Med 387:205\u2013216. https:\/\/doi.org\/10.1056\/NEJMoa2206038","journal-title":"N Engl J Med"},{"key":"549_CR45","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L et al (2023) Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med 389:877\u2013888. https:\/\/doi.org\/10.1056\/NEJMoa2302392","journal-title":"N Engl J Med"},{"key":"549_CR46","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"A Jastreboff","year":"2023","unstructured":"Jastreboff A, Kaplan LM, Frias J et al (2023) Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med 389:514\u2013526. https:\/\/doi.org\/10.1056\/NEJMoa2301972","journal-title":"N Engl J Med"},{"key":"549_CR47","doi-asserted-by":"publisher","first-page":"1043595","DOI":"10.3389\/fendo.2022.1043595","volume":"13","author":"E Lucas","year":"2023","unstructured":"Lucas E, Simmons O, Tchang B, Aronne L (2023) Pharmacologic management of weight regain following bariatric surgery. Front Endocrinol (Lausanne) 13:1043595. https:\/\/doi.org\/10.3389\/fendo.2022.1043595","journal-title":"Front Endocrinol (Lausanne)"},{"key":"549_CR48","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-8587(19)30157-3","volume":"7","author":"AD Miras","year":"2019","unstructured":"Miras AD, P\u00e9rez-Pevida B, Aldhwayan M et al (2019) Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 7:549\u2013559. https:\/\/doi.org\/10.1016\/S2213-8587(19)30157-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"549_CR49","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamasurg.2023.2930","volume":"158","author":"J Mok","year":"2023","unstructured":"Mok J, Adeleke MO, Brown A et al (2023) Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial. JAMA Surg 158:1003\u20131011. https:\/\/doi.org\/10.1001\/jamasurg.2023.2930","journal-title":"JAMA Surg"},{"key":"549_CR50","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s11695-020-04850-4","volume":"31","author":"U Thakur","year":"2021","unstructured":"Thakur U, Bhansali A, Gupta R, Rastogi A (2021) Liraglutide augments weight loss after laparoscopic sleeve gastrectomy: a randomised, double-blind, placebo-control study. Obes Surg 31:84\u201392. https:\/\/doi.org\/10.1007\/s11695-020-04850-4","journal-title":"Obes Surg"},{"issue":"1","key":"549_CR51","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","volume":"189","author":"M Fassnacht","year":"2023","unstructured":"Fassnacht M, Tsagarakis S, Terzolo M et al (2023) European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the study of adrenal tumors. Eur J Endocrinol 189(1):G1\u2013G42. https:\/\/doi.org\/10.1093\/ejendo\/lvad066","journal-title":"Eur J Endocrinol"},{"key":"549_CR52","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1677\/erc.1.01029","volume":"12","author":"DE Schteingart","year":"2005","unstructured":"Schteingart DE, Doherty GM, Gauger PG, Giordano TJ, Hammer GD, Korobkin M, Worden FP (2005) Management of patients with adrenal cancer: recommendations of an international consensus conference. Endocr Relat Cancer 12:667\u201380. https:\/\/doi.org\/10.1677\/erc.1.01029","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"549_CR53","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, Haak HR, Mihai R, Assie G, Terzolo M (2018) European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 179(4):G1\u2013G46. https:\/\/doi.org\/10.1530\/EJE-18-0608","journal-title":"Eur J Endocrinol"},{"key":"549_CR54","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1001\/jamasurg.2022.3544","volume":"157","author":"L Yip","year":"2022","unstructured":"Yip L, Duh QY, Wachtel H, Jimenez C et al (2022) American Association of Endocrine Surgeons guidelines for adrenalectomy: executive summary. JAMA Surg 157:870\u2013877. https:\/\/doi.org\/10.1001\/jamasurg.2022.3544","journal-title":"JAMA Surg"},{"key":"549_CR55","unstructured":"College of Surgeons Research Program\u00a0(2022) Operative standards for cancer surgery: volume 3 (sarcoma, adrenal, neuroendocrine, peritoneal malignancies, urothelial, hepatobiliary) American ISBN\/ISSN: 9781975153106"},{"key":"549_CR56","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0911101","volume":"363","author":"FCW Wu","year":"2010","unstructured":"Wu FCW, Tajar A, Beynon JM et al (2010) Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 363:123\u201335. https:\/\/doi.org\/10.1056\/NEJMoa0911101","journal-title":"N Engl J Med"},{"key":"549_CR57","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1056\/NEJMoa1506119","volume":"374","author":"PJ Snyder","year":"2016","unstructured":"Snyder PJ, Bhasin S, Cunningham GR et al (2016) Effects of testosterone treatment in older men. N Engl J Med 374:611\u201324. https:\/\/doi.org\/10.1056\/NEJMoa1506119","journal-title":"N Engl J Med"},{"key":"549_CR58","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa2215025","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Bhasin S, Flevaris P et al (2023) Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 389:107\u201317. https:\/\/doi.org\/10.1056\/NEJMoa2215025","journal-title":"N Engl J Med"},{"key":"549_CR59","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0430","volume":"177","author":"ANH Gravholt","year":"2017","unstructured":"Gravholt ANH, Conway GS et al (2017) Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting. Eur J Endocrinol 177:G1\u2013G70. https:\/\/doi.org\/10.1530\/EJE-17-0430","journal-title":"Eur J Endocrinol"},{"key":"549_CR60","unstructured":"Children\u2019s Hospital of Philadelphia Research Institute (2023) Pediatric Z-score calculator. https:\/\/zscore.research.chop.edu\/calcpedbonedens.php. Accessed 26 Dec 2023"},{"key":"549_CR61","unstructured":"Panzuto F, Ramage J, Pritchard DM et al (2023) European Neuroendocrine Tumor Society (ENETS) 2023"},{"key":"549_CR62","doi-asserted-by":"publisher","first-page":"e13146","DOI":"10.1111\/jne.13146","volume":"34","author":"S Grozinsky-Glasberg","year":"2022","unstructured":"Grozinsky-Glasberg S, Davar J, Hofland et al (2022) European Neuroendocrine Tumor Society (ENETS) 2022 guidance paper for carcinoid syndrome and carcinoid heart disease. J Neuroendocrinol 34:e13146. https:\/\/doi.org\/10.1111\/jne.13146","journal-title":"J Neuroendocrinol"},{"issue":"10","key":"549_CR63","doi-asserted-by":"publisher","first-page":"e13332","DOI":"10.1111\/jne.13332","volume":"35","author":"G Kaltsas","year":"2023","unstructured":"Kaltsas G, Walter T, Knigge U et al (2023) European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for appendiceal neuroendocrine tumours (aNET). J Neuroendocrinol 35(10):e13332. https:\/\/doi.org\/10.1111\/jne.13332","journal-title":"J Neuroendocrinol"},{"issue":"3","key":"549_CR64","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13105","volume":"34","author":"I Borbath","year":"2022","unstructured":"Borbath I, Pape UF, Deprez PH et al (2022) ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. J Neuroendocrinol 34(3):e13105. https:\/\/doi.org\/10.1111\/jne.13105","journal-title":"J Neuroendocrinol"},{"key":"549_CR65","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1210\/endrev\/bnab016","volume":"43","author":"HL Claahsen-van der Grinten","year":"2022","unstructured":"Claahsen-van der Grinten HL, Speiser PW, Ahmed SF et al (2022) Congenital adrenal hyperplasia-current insights in pathophysiology, diagnostics, and management. Endocr Rev 43:91\u2013159. https:\/\/doi.org\/10.1210\/endrev\/bnab016","journal-title":"Endocr Rev"},{"key":"549_CR66","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1210\/clinem\/dgad134","volume":"108","author":"K Sarafoglou","year":"2023","unstructured":"Sarafoglou K, Merke DP, Reisch N et al (2023) Interpretation of steroid biomarkers in 21-hydroxylase deficiency and their use in disease management. J Clin Endocrinol Metab 108:2154\u20132175. https:\/\/doi.org\/10.1210\/clinem\/dgad134","journal-title":"J Clin Endocrinol Metab"},{"key":"549_CR67","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14967","author":"R Pofi","year":"2023","unstructured":"Pofi R, Ji X, Krone NP, Tomlinson JW (2023) Long-term health consequences of congenital adrenal hyperplasia. Clin Endocrinol (Oxf). https:\/\/doi.org\/10.1111\/cen.14967","journal-title":"Clin Endocrinol (Oxf)"},{"key":"549_CR68","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14992","author":"C Balagamage","year":"2023","unstructured":"Balagamage C, Arshad A, Elhassan YS et al (2023) Management aspects of congenital adrenal hyperplasia during adolescence and transition to adult care. Clin Endocrinol (Oxf). https:\/\/doi.org\/10.1111\/cen.14992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"549_CR69","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41574-022-00655-w","volume":"18","author":"A Mallappa","year":"2022","unstructured":"Mallappa A, Merke DP (2022) Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nat Rev Endocrinol 18:337\u2013352. https:\/\/doi.org\/10.1038\/s41574-022-00655-w","journal-title":"Nat Rev Endocrinol"},{"key":"549_CR70","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.ghir.2018.12.004","volume":"44","author":"PF Collett-Solberg","year":"2019","unstructured":"Collett-Solberg PF, Jorge AAL, Boguszewski MCS et al (2019) Growth hormone therapy in children; research and practice: a review. Growth Horm IGF Res 44:20\u201332. https:\/\/doi.org\/10.1016\/j.ghir.2018.12.004","journal-title":"Growth Horm IGF Res"},{"key":"549_CR71","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.4158\/GL-2019-0405","volume":"25","author":"KCJ Yuen","year":"2019","unstructured":"Yuen KCJ, Biller BMK, Radovick S et al (2019) American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of growth hormone deficiency in adults and patients transitioning from pediatric to adult care. Endocr Pract 25:1191\u20131232. https:\/\/doi.org\/10.4158\/GL-2019-0405","journal-title":"Endocr Pract"},{"key":"549_CR72","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s11154-020-09605-1","volume":"22","author":"CL Boguszewski","year":"2021","unstructured":"Boguszewski CL (2021) Individual sensitivity to growth hormone replacement in adults. Rev Endocr Metab Disord 22:117\u2013124. https:\/\/doi.org\/10.1007\/s11154-020-09605-1","journal-title":"Rev Endocr Metab Disord"},{"key":"549_CR73","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1590\/S0004-27302013000900006","volume":"57","author":"CL Boguszewski","year":"2013","unstructured":"Boguszewski CL, Lacerda CS, Lacerda Filho Ld, Carvalho JA, Boguszewski MC (2013) Reappraisal of serum insulin-like growth factor-I (IGF-1) measurement in the detection of isolated and combined growth hormone deficiency (GHD) during the transition period. Arq Bras Endocrinol Metabol 57:709\u201316. https:\/\/doi.org\/10.1590\/S0004-27302013000900006","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"549_CR74","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9:847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"549_CR75","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s11154-019-09530-y","volume":"21","author":"JVO Marques","year":"2020","unstructured":"Marques JVO, Boguszewski CL (2020) Fertility issues in aggressive pituitary tumors. Rev Endocr Metab Disord 21:225\u2013233. https:\/\/doi.org\/10.1007\/s11154-019-09530-y","journal-title":"Rev Endocr Metab Disord"},{"key":"549_CR76","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3389\/fendo.2019.00432","volume":"10","author":"D Pignatelli","year":"2019","unstructured":"Pignatelli D, Carvalho BL, Palmeiro A, Barros A, Guerreiro SG, Macut D (2019) The complexities in genotyping of congenital adrenal hyperplasia: 21-hydroxylase deficiency. Front Endocrinol (Lausanne) 10:432. https:\/\/doi.org\/10.3389\/fendo.2019.00432. eCollection 2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"549_CR77","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.jpag.2017.04.001","volume":"30","author":"SF Witchel","year":"2017","unstructured":"Witchel SF (2017) (2017) Congenital Adrenal Hyperplasia. J Pediatr Adolesc Gynecol 30(5):520\u2013534. https:\/\/doi.org\/10.1016\/j.jpag.2017.04.001","journal-title":"J Pediatr Adolesc Gynecol"}],"container-title":["Hormones"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-024-00549-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s42000-024-00549-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s42000-024-00549-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T02:18:27Z","timestamp":1719973107000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s42000-024-00549-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,15]]},"references-count":77,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s42000-024-00549-8","relation":{},"ISSN":["1109-3099","2520-8721"],"issn-type":[{"value":"1109-3099","type":"print"},{"value":"2520-8721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,15]]},"assertion":[{"value":"22 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"B.O.Y., O.C., D.G.G, M.R.H., J.R.L., A.Y.L.L., D.M., M.E.P., R.P.P., D.P., H.S., J.S., S.F.W., D.Y. have no relevant disclosures to report. C.L.B. has received consultant\/speaker fees from Novo Nordisk, Recordati and Ipsen; participated as clinical investigator in international multicentric trials of Crinetics. M.C.D.B. has received consultant\/speaker fees from Novo Nordisk and Pfizer. L.B. has received honoraria for lectures from Rhythm Pharmaceuticals and PronoKal as well as payment of honoraria for attendance to advisory boards from Lilly, Pfizer, Bruno Farmaceutici, and Novo Nordisk. G.E.F. has received travel support from Abiogen. G.D.H. is the founder of Millendo Therapeutics. G.K. has received honoraria from Ipsen, Sanofi, Recordati and research funds from Ipsen, Recordati, FARAN and Pfizer. A.L. has received consulting fees from Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk and Sanofi. B.M. is a shareholder and board member of Reset Health, has received advisory fees from Novonordisk, J&J Ethicon, Lilly, fees for educational work from Lilly, Novonordisk, BI, Janssen, MSD, Sanofi, Astra Zeneca, institutional research grant support from Novonordisk. M.M. has received honoraria for speaking and consulting fees from Amgen and honoraria for speaking from UCB and Alexion. M.M. is a member of the Boards of the International Osteoporosis Foundation and the American Society of Osteoporosis Practitioners and just completed a 6-year term as a Board member of the North American Menopause Society. A.D.M. has received research funding from the MRC, NIHR, Jon Moulton Charitable Foundation, Fractyl, Gila, Randox and Novo Nordisk. A.D.M. is a shareholder in the Beyond BMI clinic, which provides clinical obesity care. C.A.S. serves as a consultant to ELPEN, SteroTx, and Lundbeck pharmaceuticals; has received a research grant from Pfizer for the study and treatment of acromegaly; and holds patents on the defects and function of the PRKAR1A, PDE11A, and GPR101 genes. M.T. has received honoraria from Ipsen and FARAN. A.J.vdL has received consultancy fees or speakers fee of Amolyt Pharma SA, Crinetics Inc and Ipsen Pharma.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}